May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Early Treatment of Perioperative Allergic Conjunctivitis Prolongs Corneal Allograft Survival
Author Affiliations & Notes
  • D.F. Larkin
    Moorfields, London, United Kingdom
  • T.H. Flynn
    Institute of Ophthalmology, London, United Kingdom
  • M. Ohbayashi
    Institute of Ophthalmology, London, United Kingdom
  • Y. Ikeda
    Institute of Ophthalmology, London, United Kingdom
  • S.J. Ono
    Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships  D.F. Larkin, None; T.H. Flynn, None; M. Ohbayashi, None; Y. Ikeda, None; S.J. Ono, None.
  • Footnotes
    Support  Irish College of Ophthalmologist/ Pfizer Fellowship, Fight for Sight, Special Trustees of Moorfields Eye Hospital
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1302. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D.F. Larkin, T.H. Flynn, M. Ohbayashi, Y. Ikeda, S.J. Ono; Early Treatment of Perioperative Allergic Conjunctivitis Prolongs Corneal Allograft Survival . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1302.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Perioperative allergic conjunctivitis increases the risk of corneal allograft rejection. Th2 cells and eosinophils have been implicated in graft rejection in recipients with allergic conjunctivitis. The aim of this study was to investigate the effects of treatment of allergic conjunctivitis with topical olopatadine, topical dexamethasone 0.1% or both on corneal allograft graft survival.

Methods: : Four groups of female A/J mice were sensitised with repeated intraperitoneal and topical administration of short ragweed pollen (SRW) and underwent corneal allografts (full MHC and multiple minor histocompatibility antigen mismatch). Mice were then treated topically twice daily for the first post–operative week as follows: Phosphate–buffered saline (n=8), olopatadine (n=7), dexamethasone 0.1% (n=8) or dexamethasone 0.1% + olopatadine ( n=7). Graft survival and infiltrating cell phenotype in rejected grafts were compared between groups.

Results: : Treatment with dexamethasone 0.1% led to a significant prolongation in corneal allograft survival (Median Survival Time, MST = 29 days) when compared with treatment with PBS (MST=20 days). Graft survival in the group treated with twice daily olopatadine alone (MST = 24 days) was not significantly different from that of those treated with PBS. Treatment with both dexamathasone and olopatadine (MST= 55 days) significantly prolonged graft survival compared with PBS. However survival in this group was not significantly better than those treated with dexamethasone alone.

Conclusions: : Short–duration (7days) treatment of peri–operative allergic conjunctivitis with topical dexamethasone, but not olopatadine, decreases the rate of subsequent corneal allograft rejection. Combined dexamethasone and olopatadine does not significantly augment graft survival compared to dexamethasone alone..

Keywords: cornea: endothelium • transplantation • immunomodulation/immunoregulation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.